HOME

Learning About Liver Fibrosis (2003)

Back to Main Page

 

  The Role of Antiviral Therapy in the Natural History
of Hepatitis C Fibrosis
  PEG interferon and ribavirin reduce liver fibrosis rate in hepatitis C
  Natural history of liver fibrosis in hepatitis C virus infection
  Fibrosis what does it mean ?
  Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? (see Editorial below by Nezam Afdahl, MD)

 

 

The Role of Antiviral Therapy in the Natural History
of Hepatitis C Fibrosis

Joanne C. Imperial, MD
Associate Professor of Medicine
Stanford University School of Medicine

The development of liver fibrosis is a critical event in the natural history of chronic hepatitis C virus infection.  Fibrosis is the predominant cause of morbidity and mortality from this disease and is responsible for the development of liver decompensation, hepatocellular carcinoma and death in a percentage of chronically-infected individuals.

Liver biopsy is considered mandatory for accurate staging of early fibrosis.  A recent prospective study was done to assess the accuracy of a combination of serum biochemical markers for diagnosing fibrosis, including early stages.  Eleven serum markers were assessed, as well as the METAVIR fibrosis stage.  A fibrosis score combining the most informative markers and taking into account age and gender was constructed.  High negative-predictive values were obtained for scores ranging from 0 to .10 and high positive-predictive values were obtained for scores ranging from .6 to 1.0.  Using a combination of simple serum markers to predict fibrosis could potentially lead to a 50% reduction in the number of liver biopsies performed in patients with chronic HCV.  A serum hyaluronic acid level of <110 mcg/l was associated with a 97% negative predictive value for significant fibrosis.

The effect on hepatic fibrosis using pegylated interferons has recently been studied by several investigators.  Heathcote randomized 271 patients with bridging fibrosis or cirrhosis to receive either interferon alfa-2a 3MU TIW, peginterferon alfa-2a 90 mcg QW or peginterferon alfa-2a 180 mcg QW.  SVR was reported in 8%, 15% and 30% of these treatment groups. In a subset of patients who underwent paired liver biopsies, histologic response (greater than a 2-point decrease in a total Histologic Activity Index score) at week 72 was 31%, 44% and 51% respectively.  Even among those individuals that did not have a sustained response to treatment, histologic improvement was observed in approximately 33% of patients.  Poynard pooled individual data from 3010 treatment-naïve patients with pre and post treatment liver biopsies from four randomized treatment trials.  Ten different regimens combining standard interferon, pegylated interferon, and ribavirin were compared.  Improvement in inflammation and necrosis varied from 39% in patients treated with standard interferon monotherapy for 24 weeks to 73% in those treated optimally with peginterferon and ribavirin.  All regimens reduced the annual rate of fibrosis progression compared with pretreatment rates. Fibrosis stage, sustained viral response, age less than 40 years, body mass index of <27 kg/m, minimal pretreatment inflammation, and viral load less than 3.5 million copies/mL were independent factors associated with the absence of significant fibrosis after treatment in this analysis.

Although the goal of antiviral therapy is to achieve sustained viral eradication, recent studies have suggested that secondary goals of preventing progression of fibrosis or liver cancer can be accomplished, even in treatment nonresponders.  Several retrospective studies to date and one recent prospective study have documented prevention of HCC after 24 or 48 weeks of therapy with interferon monotherapy in patients who do not have a sustained viral response. There is only one published, controlled trial to date using interferon maintenance therapy and the results demonstrated that continuing interferon for two years in a subpopulation of nonresponders stabilized fibrosis and reduced inflammation on serial liver biopsies.

Risk factors for progressive fibrosis include age >40 years at acquisition of HCV infection, presence of bridging fibrosis on initial liver biopsy, increased body weight with hepatic steatosis, excess alcohol consumption >25 g/d, excess hepatic iron, and immunosuppression.  There are no prospective studies that have looked at concomitant therapy using antifibrotic agents or cytoprotective drugs in prevention of hepatitis C fibrosis progression.  Colchicine and ursodeoxycholic therapy have no direct antiviral effect, but no data is available regarding the role of these drugs as long-term therapy in patients with HCV cirrhosis.  Vitamin E has some benefit in reducing ALT levels in patients with HCV infection, but has not been studied prospectively as an antifibrotic agent. 

Ongoing studies are planned specifically to examine the role of antiviral therapy on progression of fibrosis and clinical hepatitis C-related liver disease.  There are two studies that have been launched to evaluate maintenance therapy using pegylated interferons: the HALT-C trial, sponsored by the NIH, and the COPILOT (Colchicine vs PegIntron Long-Term), sponsored by Schering Hepatitis Innovations.  Both studies are planning to evaluate the effect of four years of treatment on the progression of fibrosis and development of liver failure and/or hepatocellular carcinoma.  Together, these studies should resolve the very important question regarding the role of antiviral therapy in the natural history of hepatitis C fibrosis.

 References

 1.     Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med 107:27S-30S, 1999.

2.     Heathcote EJ, Shiffman ML, Cooksley, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-1680, 2001.

3.   Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on prgression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131-1137, 2000.

4.   Poynard T, Ratziu V, Benhamou Y, Di Martino VD, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and signficance. Semin Liver Dis 20:47-55, 2000.

5.   Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117: 1165-1172, 1999.

PEG interferon and ribavirin reduce liver fibrosis rate in hepatitis C

A combination of pegylated interferon and ribavirin significantly reduces
the rate of fibrosis progression in patients with hepatitis C, according to
research published in the May issue of Gastroenterology.

A group of international researchers evaluated the effect of pegylated
(PEG) interferon alfa-2b and ribavirin on liver fibrosis in patients with
chronic hepatitis C.

Individual data from 3010 naive patients, with pretreatment and
post-treatment biopsies from 4 randomized trials, were pooled.

Ten different regimens combining standard interferon, PEG interferon, and
ribavirin were compared.

The impact of each regimen was estimated by the percentage of patients with
at least one grade improvement in the necrosis and inflammation (METAVIR
score).

It was also assessed by the percentage of patients with at least one stage
worsening in fibrosis METAVIR score, and by the fibrosis progression rate
per year.

Necrosis and inflammation improvement ranged from 39% (interferon, 24
weeks) to 73% (optimized PEG interferon and ribavirin).

Fibrosis worsening ranged from 23% (interferon, 24 weeks) to 8% (optimized
PEG interferon and ribavirin).

The team found that all regimens significantly reduced the fibrosis
progression rates in comparison to rates before treatment.

Furthermore, the reversal of cirrhosis was observed in 49% of 153 patients
with baseline cirrhosis.

Necrosis and inflammation improved by 73% with PEG interferon and ribavirin.
Gastroenterology

Six factors were found to be independently associated with the absence of
significant fibrosis after treatment.

These included baseline fibrosis stage (odds ratio [OR] = 0.12), sustained
viral response (OR = 0.36), and age less than 40 years (OR = 0.51).

The other associated factors were body mass index less than 27 kg/m2 (OR =
0.65), no or minimal baseline activity (OR = 0.70), and viral load less
than 3.5 millions copies per milliliter (OR = 0.79).

Professor Thierry Poynard, of the University of Paris VI, Paris, France,
concluded on behalf of the group, "PEG-interferon and ribavirin combination
significantly reduces the rate of fibrosis progression in patients with
hepatitis C."

In an accompanying Editorial, Professor Michael J.P. Arthur, of Southampton
General Hospital, England, comments, "The study of Poynard et al.
challenges all of us to accept that the traditional view of cirrhosis as a
progressive, irreversible disease is no longer correct.

"This augurs well for the future of our patients with chronic HCV
infection, particularly if they clear the virus with treatment," he adds.

"The study also encourages further scientific investigation of the key cell
and molecular mechanisms of liver fibrosis.

"It raises the prospect that an antifibrotic agent, aimed at promoting
regression of disease, may be an important therapeutic strategy for the
future," he concludes.

Gastroenterology 2002; 122(5): 1303-13
03 May 2002

 

Natural history of liver fibrosis in hepatitis C virus infection

URL:http://www.gastrohep.com/news/news.asp?id=1907



Researchers from England and France find that demographic features account
for a minority of fibrosis rate variability.

The rate of development of liver fibrosis in hepatitis C virus (HCV)
infection varies between individuals.

In this study, researchers determined whether fibrosis progresses linearly
through the grading scales. They also identified factors influencing the
rate of fibrosis.

The team's findings are published in the April issue of Gut.

The researchers identified 917 HCV infected patients, who had undergone at
least 1 liver biopsy.

They scored the biopsies were scored using the modified HAI (Ishak) and
METAVIR systems. These 2 systems were compared.

Male sex, older age at infection, and viral genotype are associated with
more rapid fibrosis progression.
Gut

All patients were treatment naive at first biopsy.

Researchers examined demographic features for their relationship to
fibrosis rate using univariate and multivariate analysis.

In addition, a subgroup of patients who had 2 biopsies was examined to test
the assumption that fibrosis progresses in a linear fashion.

The research team found that male sex, older age at infection, and viral
genotype non-1 were all associated with a rapid rate of fibrosis. Using
multiple linear regression, they determined that these factors accounted
for 30% of the variability in fibrosis rate.

The team also found that the METAVIR and Ishak scores were highly correlated.

However, in the 137 patients who had 2 biopsies, the predicted probability
for an increase of 1 on the fibrosis score was too low to assess linearity.

Dr Wright's team concluded, "Demographic features account for a minority of
fibrosis rate variability".

"The Ishak and METAVIR scoring systems are equivalent."

"Linearity of fibrosis progression cannot be assessed in biopsies only a
few years apart."

Gut 2003; 52: 574-9
13 March 2003

 

Fibrosis what does it mean ?
   

Inflammation

Inflammation is a very complex cellular and biochemical event that occurs when vascular tissue (like the liver) is injured or traumatized.

The inflammatory process can be initiated by many factors, but we are primarily concerned with the liver's inflammatory response to the hepatitis virus.

The acute inflammatory response to injury begins immediately, and usually begins to resolve within a few hours or days. In hepatitis, however, the persistant assault by the hepatitis virus results in chronic inflammation. Eventually, inflammation will result in tissue changes and necrosis (death) at the cellular level. As this process continues, the patient begins to develop Fibrosis (scarring).

Fibrosis

In general, the term Fibrosis refers to the abnormal formation of fibrous (scar) tissue. For hepatitis patients, fibrosis means that the liver has been under assault by the hepatitis for some time.

Early stages of fibrosis are identified by discrete, localized areas of scarring in one portal (zone) of the liver. Later stages of fibrosis are identified by "bridging" fibrosis, which is scar tissue that crosses across zones of the liver.
The rate at which people progress from inflammation to fibrosis, and eventually to Cirrhosis seems to vary tremendously, but in most people the progression is very slow.

There is a growing body of evidence that people who respond to interferon therapy for HCV infection may experience a decrease in the amount of tissue scarring. This speaks to the liver's ability to regenerate itself. If fibrosis advances far enough, it is described as Cirrhosis.

Liver biopsy is conducted to assess the degree of inflammation (grade) and degree of scarring (stage).

 
 
Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? (see Editorial below by Nezam Afdahl, MD)
 
 
 
  Noninvasive prediction of fibrosis in patients with chronic hepatitis C
 
Hepatology, May 2003, Volume 37, Number 5. Thierry Poynard, M.D., Ph.D. et al.
 
To the editor:
 
In a cohort of 476 untreated patients with chronic hepatitis C virus (HCV), Forns et al. (Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-992) recently developed an index that accurately identified patients with minimal hepatic fibrosis (METAVIR stage < F2). This index, including age, platelets, -glutamyl-transpeptidase, and cholesterol had good discriminative power, as shown by an area under the receiver operating characteristic (ROC) curve of .81 in the validation cohort (n = 125). As discussed by the authors, our group also has derived and validated a fibrosis index (Fibrotest; Biopredictive, Houilles, France) that includes 5 biochemical markers (apolipoprotein A1, haptoglobin, 2-macroglobulin, -glutamyl transpeptidase, and total bilirubin) and shows high predictive values.
 
We sought to compare these indices by using data collected retrospectively in 249 patients from our original population with complete biochemical data. In this group, the prevalence of F2-F4 fibrosis was 38%, and HCV genotypes (n = 136 with available data) were 1 (63%), 2 (13%), 3 (19%), 4 (4%), and 5 (2%). The areas under the ROC curves (±SE) for the identification of F2-F4 fibrosis were 0.78 ± 0.03 for the Forns index versus 0.84 ± 0.02 for the Fibrotest (P = .02), suggesting that the latter has greater discriminative power.8 Moreover, an index including the 4 variables of Forns et al. derived in our population by using stepwise forward multiple logistic regression yielded nearly identical results (area under the ROC curve, 0.78 ± 0.03). There was a continuous, almost linear, relationship between Fibrotest and the fibrosis stage, with significant differences between stages that were not observed for the Forns et al.
 
In addition to superior diagnostic power, the Fibrotest has several advantages over the index of Forns et al.1 First, the Fibrotest is not genotype dependent, whereas the Forns et al.1 index includes serum cholesterol, which varies with HCV genotype. Patients with genotype 3 have lower cholesterol levels, which increase after viral eradication.9,10 Although 85% of the Spanish cohort had genotype 1 (genotype 3 prevalence was not reported), the prevalence in most populations, including our own, is lower. In countries where genotype 3 is more common (e.g., in Asia), use of this index may not be advisable.
 
Second, the Forns et al.1 index includes the platelet count, which is poorly standardized between laboratories. We did not include platelets in the Fibrotest so as to avoid this limitation and develop an index that is easily automated using minimal equipment. Apolipoprotein A1, haptoglobin, and 2-macroglobulin, the nonroutine components of the Fibrotest, can be measured using a single autoanalyzer and have minimal interlaboratory variability (coefficients of variation < 6%).
 
Third, the Fibrotest has been validated in several cohorts, including patients with human immunodeficiency virus/HCV-coinfection, who often have human immunodeficiency virus- or medication-related thrombocytopenia. Moreover, the Fibrotest is responsive to changes in fibrosis attributable to interferon-based therapy. Finally, a combination of alanine aminotransferase levels and the Fibrotest (Actitest; Biopredictive) accurately predicts the severity of necro-inflammatory activity, another important histologic feature. Both tests are easy to perform and are available on the internet at www.biopredictive.com.
 
In conclusion, this retrospective comparison suggests that the Fibrotest provides a more accurate estimate of HCV-related fibrosis than the index of Forns et al. Prospective comparisons in additional centers are warranted to confirm this finding.
 
EDITORIAL
Nezam H. Afdhal, M.D.
Liver Center, Beth Israel Deaconess Medical Center, Boston, MA
 
One of the major clinical problems facing the hepatology and gastroenterology community is how best to evaluate and manage the increasing numbers of patients identified with hepatitis C virus (HCV). In the last decade, advances in serologic and virologic testing for HCV and improvements in therapy have led more patients to be identified and to seek treatment. However, little progress has been made in improving either our ability to determine the degree of hepatic injury, particularly fibrosis, or to predict the risk of disease progression for the individual patient. This information still requires an old fashioned liver biopsy. The clinician relies on the biopsy results for both prognostic and therapeutic decision making, which can have a major impact on the patient's life. While we certainly are daunted at the prospect of performing 3 million liver biopsies with the associated cost, manpower issues, and risk for patient injury, we need to have a reliable alternative that can just as effectively guide our decision analysis.
 
Multiple histologic scoring systems have been proposed for the grading of HCV inflammation and the staging of HCV fibrosis, including the commonly used METAVIR and Ishak scoring systems. The pathologist is able to use these systems to grade the inflammatory component of HCV and stage the degree of fibrosis. Repeat liver biopsies can determine the effect of therapy on improving liver inflammation and fibrosis and the true rate of disease progression in individuals who decline therapy. Perhaps the first question we should ask is, how good is our gold standard of liver biopsy for staging HCV-induced liver fibrosis? A single-pass liver biopsy is able to correctly diagnose the stage of fibrosis or presence of cirrhosis in 80% of patients.5 Factors that improve the diagnostic accuracy of liver biopsy include the presence of a uniform disease throughout the liver such as HCV, multiple passes, use of a Trucut 15-gauge needle rather than Menghini type needles, and an unfragmented biopsy core of 2 cm or greater in length. Even with experienced physicians performing the liver biopsy and expert pathologists interpreting the biopsy, our gold standard has up to a 20% error rate in staging disease.
 
In addition, the actual role of liver biopsy in HCV is controversial. The liver biopsy is not necessary to make the diagnosis and rarely is it of value in excluding secondary diagnoses such as coexistent, autoimmune, iron, nonalcoholic steatohepatitis or alcohol-induced injury. The major clinical utility of the index biopsy in HCV is to enable the clinician to determine the need for therapy. Because of the complexity and side effects of interferon-based therapies for HCV, the liver biopsy has taken an increasing role in the clinician's decision whether to treat a patient. Patients with significant liver fibrosis (METAVIR >F2 or Ishak >F3) or moderate inflammation are all considered as suitable for therapy, whereas patients with milder disease are often not as aggressively offered treatment. However, as therapy for HCV improves, the clinical need for a biopsy may be less apparent. For example, genotype 2 and 3 patients have a greater than 70% sustained virologic response with pegylated interferons and ribavirin, and in uncomplicated cases a rationale can be made to treat all these patients without liver biopsy and only to biopsy those who fail treatment. As newer, better tolerated, and more efficacious therapies are developed, the need for biopsying all HCV patients to grade and stage disease may become redundant. Therefore, the development of noninvasive tests that can differentiate between patients with mild disease (METAVIR F0 or F1) versus those with more significant fibrosis (METAVIR F2-F4) could have a widespread clinical utility in managing HCV patients in the future.
 
This concept of attempting to use noninvasive serum tests to classify patients as having mild or significant liver fibrosis was addressed in a recent publication by Forns et al. and in several letters in this issue of HEPATOLOGY. Forns examined a selected cohort of patients with HCV and, by using multiple logistic regression, identified age and 3 commonly performed serum tests that could be used to predict patients with F0/F1 disease. They derived a formula giving a numerical score in an initial population of 351 HCV patients, which was based on the patient age combined with single estimations of glutamyl transpeptidase (GGT), cholesterol level, and platelet count. This score was then validated in a prospective group of 125 patients, in which 92 patients had mild fibrosis and 33 patients had significant fibrosis. A score of less than 4.2 was seen in 47 patients of whom 45 (96%) had stage F0/F1 giving an overall accuracy of 96% in identifying patients with mild fibrosis. A score of greater than 6.9 was taken as the high cutoff point for significant fibrosis. Only 10 of 33 patients with stage F2 to F4 were identified by this scoring system, and 15 patients with F0 to F1 were incorrectly classified as having advanced disease. The authors concluded that this relatively simple, inexpensive fibrosis scoring system could prevent the need for a liver biopsy in one third of patients with mild disease.
 
Certainly, on preliminary analysis this looks promising but there are several important considerations. First, the patient population was highly selected to exclude patients over 65 years of age, those with regular alcohol consumption, obese patients, and patients coinfected with HBV or human immunodeficiency virus. More importantly, only 51% of the patients studied could actually be classified, and the scoring system was indeterminate for the remainder of the patients who scored between 4.2 and 6.9. Therefore, the widespread applicability of such a fibrosis scoring system might be limited.
 
Interestingly, two separate groups have validated the findings of Forns et al. in separate cohorts of HCV patients. Patel et al. in their letter in this edition of HEPATOLOGY applied the Forns scoring system to 110 HCV patients. A score of less than 4.2 had a negative predictive value of 89%, but 59% of patients were again in the indeterminate group and could not be classified. Thabut et al. in their letter compare the Forns score to the previously published FIBROTEST.12 The FIBROTEST utilizes 5 less commonly used biomarkers for fibrosis including apolipoprotein A1, haptoglobin, alfa 2 macroglobulin, GGT, and total bilirubin. In their retrospective analysis, the FIBROTEST appeared slightly better at diagnosing significant fibrosis and showed a more linear correlation with degree of fibrosis than the Forns scale. Both FIBROTEST and the Forns scale were excellent at excluding fibrosis, but the FIBROTEST had a greater positive predictive value (90%) for diagnosing advanced fibrosis. However, it is critical to point out that neither of these tests can truly distinguish between the different histologic stages of fibrosis. In addition, the FIBROTEST has similar issues with a large percentage of patients falling into an indeterminate group. The inability to classify large numbers of patients is not surprising because neither of these systems really measures fibrosis but they both rather reflect alterations in hepatic function associated with progressive disease. More recently, combining markers of extracellular matrix (ECM) such as tissue inhibitor of metalloproteinase and hyaluronic acid with alfa 2 macroglobulin, a marker of hepatic function, has been evaluated by Patel et al. This combination of fibrosis markers has a similar ability to differentiate F0/F1 from F2 to F4 and reduces the number of patients (20%-30% depending on fibrosis prevalence) falling into the indeterminate range.
 
First, all of these investigators should be congratulated for pursuing clinically relevant noninvasive methods to measure liver fibrosis. There is little doubt that we need such surrogate fibrosis markers or scoring systems for HCV, particularly as we start to develop a new generation of antifibrotic therapies. Several large studies are already in progress to evaluate both alfa and gamma interferons as antifibrotic agents in HCV and all are relying on serial liver biopsies as the primary outcome determinant. However, biopsies remain a static determinant of the mass of fibrosis at a given time, and an antifibrotic agent could be highly effective in ECM remodeling but show little change on biopsy. This is where the utility of true fibrosis markers is critical. An ideal noninvasive surrogate marker of liver fibrosis should be liver specific; not influenced by alterations in liver, renal, or reticuloendothelial cell function; reproducible; and easy to perform. These markers should also reflect the stage of fibrosis for diagnostic purposes and the dynamic balance of matrix deposition and removal. Finally, they should be specific for liver fibrosis from any cause and be independent of any associated hepatic inflammation. Advances in our understanding of the hepatic ECM has led to many potential markers being identified, but none have sufficient merit for clinical use as solitary markers. A large multicenter European study combining multiple markers that measure ECM production and breakdown has shown promise in the diagnostic staging of liver disease, and further longitudinal studies from this cohort are awaited.
 
So, are surrogate markers of liver fibrosis ready for clinical primetime? We could argue from the study by Forns et al. and the FIBROTEST that we can, to some extent, categorize almost a third of patients into those with mild disease and use this information for decision analysis without a liver biopsy. Unfortunately, there is somewhat of a rush to commercialize these so-called tests of liver fibrosis without rigorous scientific validation. I would propose that the clinical acceptance of fibrosis markers will depend on their fulfilling the ideal characteristics listed above. We need to focus basic and clinical research efforts on identifying better fibrosis markers and exploring how to incorporate them into clinical practice. The study of Forns et al. and others are a good beginning in our quest for surrogate markers, but for the moment, the pendulum still favors biopsy over blood. 		 
 
 http://www.natap.org/
 

 
Reviewed Feb 2004
HOME Liver Cancer
FAQ Great Place To Start Autoimmune Hepatitis
Have You Just Been Diagnosed ? Other Medical Conditions & HCV
Glossary HCV Worldwide News & Research
History Of HCV HCV News Archives 2001-2002
Your Liver Functions Internet Conference Reports on All New and Current HCV Therapies
Symptoms Of HCV Nutrition & HCV
Transmission Of HCV Interviews: Members & Professionals
Sex And HCV HCV Support Groups Listed By State
Understanding Your Blood Tests  Labs Transplant Support Groups Listed By State
Monitoring Blood Work On Treatment Insurance, Financial Aid & Free Meds
Liver Biopsy Understanding Your Results How to Find a Doctor & What to Ask
Viral Loads Members Share Their First Shot Experience
Genotypes Shared Stories From Our  Members
Infergen Your Questions & HCV
 Inhibitors &  New Therapies Chat Room & Message Boards
Peg Intron & Pegasys Books On HCV
Help With Side Effects During Treatment Food For The Soul Inspirational Stories
Drug Interactions & Treatment Informative Links
Latest HCV Trials Pictures Of Our Members
Liver Fibrosis What's New at Janis and Friends
Cirrhosis Sign Our Guestbook
Transplants Contact Us mailto:JansDream@angelhaven.com
Current Transplant Research In Memory Of Janis